Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors

Wang, Ruoting; Li, Wenli; Lazarus, Jeffrey V.; Schiattarella, Gabriele G.; Lip, Gregory Y.H.; Liu, Yingxin; Chen, Yujiong; Qi, Lu; Van Spall, Harriette G.C.; Li, Guowei

Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors

Tools

Preview	PDF (Accepted Manuscript) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 3MB
	Other (Supplementary Information) 1MB

Item Type:	Article
Title:	Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors
Creators:	Wang, Ruoting, Li, Wenli, Lazarus, Jeffrey V., Schiattarella, Gabriele G. ORCID: https://orcid.org/0000-0002-7582-7171, Lip, Gregory Y.H., Liu, Yingxin, Chen, Yujiong, Qi, Lu, Van Spall, Harriette G.C. and Li, Guowei
Abstract:	BACKGROUND: While metabolic dysfunction-associated steatotic liver disease (MASLD) has been consistently associated with increased cardiovascular risk in the general population, its association with cardiovascular disease (CVD) mortality in adults with established cardiometabolic risk factor (including obesity, hypertension, diabetes mellitus, or dyslipidemia) remains inconsistent. We aimed to determine whether frailty confounds the MASLD-CVD mortality association. METHODS: We analyzed 10,413 US NHANES III adults with ≥ 1 cardiometabolic risk factor. Frailty was quantified using a 49-item frailty index (FI, ranging from 0 [maximal robustness] to 1 [severe frailty]) and categorized into quartiles. Associations between MASLD and CVD mortality were assessed using multivariable Cox proportional hazards models with and without frailty adjustment. Interaction and mediation analyses were also performed. RESULTS: Over a mean follow-up of 23.36 years, 1,375 (13.20%) CVD deaths occurred. Frailty was significantly associated with both MASLD and CVD mortality. There was no evidence of interaction between MASLD and frailty, and mediation analysis showed no indirect effect of MASLD on CVD mortality through frailty. In absence of frailty adjustment, MASLD was not associated with CVD mortality (HR = 0.92, 95% CI: 0.78-1.10). After adjustment for frailty, MASLD was independently associated with higher CVD mortality (HR = 1.19, 95% CI: 1.07-1.32). Stratified by FI quartiles, significant associations were observed only in the higher frailty quartiles (Q3: HR = 1.35, 95% CI: 1.03-1.77; Q4: HR = 1.70, 95% CI: 1.07-2.69). The population attributable fraction of MASLD for CVD mortality was 10.1-12.5% after frailty adjustment. CONCLUSIONS: Frailty may confound the MASLD-CVD mortality relationship in people with cardiometabolic risk factors. The association between MASLD and CVD mortality is detected only when frailty is adjusted for.
Keywords:	Metabolic Disorder, Hepatic and Cardiometabolic Interconnections, MASLD, Frailty, Epidemiology
Source:	Cardiovascular Diabetology
ISSN:	1475-2840
Publisher:	BioMed Central
Date:	11 July 2026
Official Publication:	https://doi.org/10.1186/s12933-026-03284-z
PubMed:	View item in PubMed
Related to:	URL URL Type https://wwwn.cdc.gov/nchs/nhanes/nhanes3/default.aspx External Dataset

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year